Bladder cancer is one of the tumors that threaten human health, with the fourth highest incidence. EIF2S1 is reported to regulate the ATF4 pathway and related to the autophagy for cancer therapy. To study the expression of a new type of bladder cancer treatment target related protein EIF2α in bladder urothelial carcinoma tissue.

By the TCGA database analysis website UALCAN, we found that EIF2S1 gene expression was not significantly different in normal bladder tissue and bladder cancer cells, but DNA methylation level of EIF2S1 was much lower in bladder cancer cells. We then performed EIF2α protein expression detection on 31 pairs of bladder cancer and normal bladder tissue specimens, and interpreted the staining intensity (0/1+/2+/3+) of the antibody's nucleus and cytoplasmic staining and the positive rate of staining. Interpret the cancer tissue and the adjacent tissue (epithelial) separately. Staining intensity score: 0 points (negative), 1 point (I), 2 points (II), 3 points (III). Staining positive rate score: 0 points (negative), 1 point (1-25%), 2 points (26%-50%), 3 points (51-75%), 4 points (76%-100%). Groups are grouped by the product of "staining intensity score" and "staining positive rate...

...read more

The results shows: the primary antibody dilution ratio of 1:100 was used to detect the expression of eIF2a gene in the tissue chip; the immunostaining of eIF2a gene was significantly different, and the immunostaining of the bladder cancer group was significantly higher than that of the normal bladder tissue group.

We found through immunohistochemistry that the protein encoded by EIF2S1 gene, EIF2α, was significantly higher expressed in bladder urothelial carcinoma.